|Day Low/High||220.01 / 225.49|
|52 Wk Low/High||215.78 / 344.00|
In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.
AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.
With a third of S&P 500 stocks having reported, these 3 trends are coming to the fore.
Equities are a bit higher across the board since our last update. Homebuilders continue to be in the green as 30-year mortgage rates hover near three-year lows. This is starting to have an effect as purchase application demand has posted its biggest...
I am happy to be sitting back in for Doug Kass on the Daily Diary. I look forward to an active live chat arena today. We certainly have a lot of potential discussion topics. Second-quarter earnings reports will continue to hit the wires in a fast an...
Be zen and keep emotions out of investing decisions. It can pay off in higher portfolio returns.
Use buy-write orders as a conservative way to invest in GILD in these uneasy times.
There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.
Buyers have returned in recent months and the stock could be ready to rise.
The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.
After a five-year hiatus I'm ready to start throwing whammies in several directions.
RMPIA outperformed once gain during April.
Analyzing this year's stock draft contest and individual stock-picking vs. indexing.
Bitcoin, the most famous of all crypto-currencies, has enjoyed something of a rebound of late.
For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.
Screening Goldman Sachs' list of the top 20 stocks to see which ones are the best technical opportunities.
The potential for so-so earnings results among the S&P 500 and an initial lackluster response to IPOs could cause investors to pause a bit after a strong first three months of 2019.
Buy-write strategies give you confidence to 'buy the dip' while also adding an extra income stream.
The biotech sector isn't for the faint of heart, but these two companies issued promising news this week.
All the money in the world cannot change the fact that rising stock prices and falling earnings make the market more expensive.
Biogen shareholders are taking a beating on cancellation of trials for its Alzheimer's drug candidate.
Biogen has to now be considered a more likely buyout target given the breadth of its product portfolio.
What we have seen of late from a number of chip producers really might be interpreted as pre-recessionary.
And it is happening not a moment too soon.
Avoid the long side of Biogen as the October low is likely to be tested or broken in the days ahead.